Stockreport

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx® (cabozantinib) versus placebo in [Read more]